Table 1.

Descriptive variables in our cohort.

Characteristics of the Patients at baseline	N (55)	%
Age (median)	65[39,62,64–67]
Sex ❑Male ❑Female	39 16	70.9 % 29.1 %
Race ❑White	55	100 %
Smoking status ❑Current or former ❑Never	53 2	96.4 % 3.6 %
Body mass index ❑<30 kg/m2 ❑>30 kg/m2	46 9	83.6 % 16.4 %
Eastern Cooperative Oncology Group scale ❑0 ❑1	36 19	65.5 % 34.5 %
Histologic features ❑Squamous cell carcinoma ❑Adenocarcinoma	22 33	40 % 60 %
Stage ❑III ❑IV	16 39	29.1 % 70.9 %
Treatment indication ❑Locally advanced ❑First-line ❑Successive lines	14 18 23	25.5 % 32,7 % 41.8 %
PD-L1 expression ❑<1 % ❑1–49 % ❑>50 % ❑Unknown	10 21 16 8	18.2 % 38.2 % 29.1 % 14.5 %
ICI drug ❑Pembrolizumab ❑Atezolizumab ❑Durvalumab ❑Nivolumab	21 18 14 2	38.2 % 32.7 % 25.5 % 3.6 %
Best response ❑Complete ❑Partial ❑Stable disease ❑Progression ❑Not evaluable	10 13 12 15 5	18.8 % 23.6 % 21.8 % 27.3 % 9.1 %
Antibiotic treatment ❑Yes ❑No	28 27	50.9 % 49.1 %
Timing of antibiotic use ❑2 months before – 1 month after ICI start ❑>1 month after ICI start	22 33	40 % 60 %
Corticosteroid treatment ❑Yes ❑No	32 23	58.2 % 41.8 %
Timing of corticosteroid use ❑2 months before until first ICI cycle ❑After first ICI cycle	9 23	28.1 % 71.9 %